Cargando…
Drug Resistance Conferring Mutation and Genetic Diversity of Mycobacterium tuberculosis Isolates in Tuberculosis Lymphadenitis Patients; Ethiopia
BACKGROUND: Tuberculosis lymphadenitis (TBLN) is a growing public health concern in Ethiopia. However, there is limited information available on gene mutations conferring drug resistance and genetic diversity of M. tuberculosis isolates from TBLN patients. METHODS: Drug resistance and genetic divers...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7894881/ https://www.ncbi.nlm.nih.gov/pubmed/33623398 http://dx.doi.org/10.2147/IDR.S298683 |
_version_ | 1783653318570016768 |
---|---|
author | Ayalew, Sosina Wegayehu, Teklu Taye, Hawult Wassie, Liya Girma, Selfu Berg, Stefan Mihret, Adane |
author_facet | Ayalew, Sosina Wegayehu, Teklu Taye, Hawult Wassie, Liya Girma, Selfu Berg, Stefan Mihret, Adane |
author_sort | Ayalew, Sosina |
collection | PubMed |
description | BACKGROUND: Tuberculosis lymphadenitis (TBLN) is a growing public health concern in Ethiopia. However, there is limited information available on gene mutations conferring drug resistance and genetic diversity of M. tuberculosis isolates from TBLN patients. METHODS: Drug resistance and genetic diversity analysis were done on 91 M. tuberculosis isolates from culture positive TBLN patients collected between 2016 and 2017. Detection of mutations conferring resistance was carried out using GenoType MTBDRplus VER 2.0. Thereafter, isolates were typed using spoligotyping. RESULTS: Out of the 91 strains, mutations conferring resistance to rifampicin (RIF) and isoniazid (INH) were observed in two (2.2%) and six (6.6%) isolates, respectively. The two RIF resistant isolates displayed a mutation at codon 531 in the rpoB gene with amino acid change of S531L. Among the six INH resistant strains, four isolates had shown mutation at the KatG gene at codon 315 with amino acid change of S315T, one isolate had a mutation at the inhA gene at codon 15 with amino acid change of C15T and one isolate had a mutation at the inhA gene with unknown amino acid change. All drug resistant isolates were from treatment naive TBLN patients. The dominantly identified Spoligo International Types (SITs) were SIT25, SIT149, and SIT53, respectively; these accounted for 43% of the total number of strains. The isolates were grouped into four main lineages; Lineage 1 (2, 2.2%), Lineage 3 (38, 41.7%), Lineage 4 (49, 53.8%) and Lineage 7 (2, 2.2%). Four out of six (66.7%) isolates with drug resistance conferring mutations belonged to clustered strains (strains with shared SIT). CONCLUSION: The detection of drug resistant conferring mutation in treatment naïve TBLN patients together with detection of drug resistant isolates among clustered strains might suggest resistant strains' transmission in the community. This needs to be carefully considered to prevent the spread of drug resistant clones in the country. |
format | Online Article Text |
id | pubmed-7894881 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-78948812021-02-22 Drug Resistance Conferring Mutation and Genetic Diversity of Mycobacterium tuberculosis Isolates in Tuberculosis Lymphadenitis Patients; Ethiopia Ayalew, Sosina Wegayehu, Teklu Taye, Hawult Wassie, Liya Girma, Selfu Berg, Stefan Mihret, Adane Infect Drug Resist Original Research BACKGROUND: Tuberculosis lymphadenitis (TBLN) is a growing public health concern in Ethiopia. However, there is limited information available on gene mutations conferring drug resistance and genetic diversity of M. tuberculosis isolates from TBLN patients. METHODS: Drug resistance and genetic diversity analysis were done on 91 M. tuberculosis isolates from culture positive TBLN patients collected between 2016 and 2017. Detection of mutations conferring resistance was carried out using GenoType MTBDRplus VER 2.0. Thereafter, isolates were typed using spoligotyping. RESULTS: Out of the 91 strains, mutations conferring resistance to rifampicin (RIF) and isoniazid (INH) were observed in two (2.2%) and six (6.6%) isolates, respectively. The two RIF resistant isolates displayed a mutation at codon 531 in the rpoB gene with amino acid change of S531L. Among the six INH resistant strains, four isolates had shown mutation at the KatG gene at codon 315 with amino acid change of S315T, one isolate had a mutation at the inhA gene at codon 15 with amino acid change of C15T and one isolate had a mutation at the inhA gene with unknown amino acid change. All drug resistant isolates were from treatment naive TBLN patients. The dominantly identified Spoligo International Types (SITs) were SIT25, SIT149, and SIT53, respectively; these accounted for 43% of the total number of strains. The isolates were grouped into four main lineages; Lineage 1 (2, 2.2%), Lineage 3 (38, 41.7%), Lineage 4 (49, 53.8%) and Lineage 7 (2, 2.2%). Four out of six (66.7%) isolates with drug resistance conferring mutations belonged to clustered strains (strains with shared SIT). CONCLUSION: The detection of drug resistant conferring mutation in treatment naïve TBLN patients together with detection of drug resistant isolates among clustered strains might suggest resistant strains' transmission in the community. This needs to be carefully considered to prevent the spread of drug resistant clones in the country. Dove 2021-02-15 /pmc/articles/PMC7894881/ /pubmed/33623398 http://dx.doi.org/10.2147/IDR.S298683 Text en © 2021 Ayalew et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Ayalew, Sosina Wegayehu, Teklu Taye, Hawult Wassie, Liya Girma, Selfu Berg, Stefan Mihret, Adane Drug Resistance Conferring Mutation and Genetic Diversity of Mycobacterium tuberculosis Isolates in Tuberculosis Lymphadenitis Patients; Ethiopia |
title | Drug Resistance Conferring Mutation and Genetic Diversity of Mycobacterium tuberculosis Isolates in Tuberculosis Lymphadenitis Patients; Ethiopia |
title_full | Drug Resistance Conferring Mutation and Genetic Diversity of Mycobacterium tuberculosis Isolates in Tuberculosis Lymphadenitis Patients; Ethiopia |
title_fullStr | Drug Resistance Conferring Mutation and Genetic Diversity of Mycobacterium tuberculosis Isolates in Tuberculosis Lymphadenitis Patients; Ethiopia |
title_full_unstemmed | Drug Resistance Conferring Mutation and Genetic Diversity of Mycobacterium tuberculosis Isolates in Tuberculosis Lymphadenitis Patients; Ethiopia |
title_short | Drug Resistance Conferring Mutation and Genetic Diversity of Mycobacterium tuberculosis Isolates in Tuberculosis Lymphadenitis Patients; Ethiopia |
title_sort | drug resistance conferring mutation and genetic diversity of mycobacterium tuberculosis isolates in tuberculosis lymphadenitis patients; ethiopia |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7894881/ https://www.ncbi.nlm.nih.gov/pubmed/33623398 http://dx.doi.org/10.2147/IDR.S298683 |
work_keys_str_mv | AT ayalewsosina drugresistanceconferringmutationandgeneticdiversityofmycobacteriumtuberculosisisolatesintuberculosislymphadenitispatientsethiopia AT wegayehuteklu drugresistanceconferringmutationandgeneticdiversityofmycobacteriumtuberculosisisolatesintuberculosislymphadenitispatientsethiopia AT tayehawult drugresistanceconferringmutationandgeneticdiversityofmycobacteriumtuberculosisisolatesintuberculosislymphadenitispatientsethiopia AT wassieliya drugresistanceconferringmutationandgeneticdiversityofmycobacteriumtuberculosisisolatesintuberculosislymphadenitispatientsethiopia AT girmaselfu drugresistanceconferringmutationandgeneticdiversityofmycobacteriumtuberculosisisolatesintuberculosislymphadenitispatientsethiopia AT bergstefan drugresistanceconferringmutationandgeneticdiversityofmycobacteriumtuberculosisisolatesintuberculosislymphadenitispatientsethiopia AT mihretadane drugresistanceconferringmutationandgeneticdiversityofmycobacteriumtuberculosisisolatesintuberculosislymphadenitispatientsethiopia |